Warning: fopen(/home/virtual/enm-kes/journal/upload/ip_log/ip_log_2024-02.txt): failed to open stream: Permission denied in /home/virtual/lib/view_data.php on line 88 Warning: fwrite() expects parameter 1 to be resource, boolean given in /home/virtual/lib/view_data.php on line 89 Characteristics of Glycemic Control and Long-Term Complications in Patients with Young-Onset Type 2 Diabetes (Endocrinol Metab 2022;37:641-51, Han-sang Baek et al.)
Skip Navigation
Skip to contents

Endocrinol Metab : Endocrinology and Metabolism

clarivate
OPEN ACCESS
SEARCH
Search

Articles

Page Path
HOME > Endocrinol Metab > Volume 37(6); 2022 > Article
Letter
Diabetes, Obesity and Metabolism Characteristics of Glycemic Control and Long-Term Complications in Patients with Young-Onset Type 2 Diabetes (Endocrinol Metab 2022;37:641-51, Han-sang Baek et al.)
May Thu Hla Aye1orcid, Sajid Adhi Raja2, Vui Heng Chong1,3orcid
Endocrinology and Metabolism 2022;37(6):943-944.
DOI: https://doi.org/10.3803/EnM.2022.1601
Published online: November 23, 2022
  • 1,542 Views
  • 162 Download

1Department of Medicine, Pengiran Muda Mahkota Pengiran Muda Haji Al-Muhtadee Billah (PMMPMHAMB) Hospital, Tutong, Brunei Darussalam

2Department of Ophthalmology, Pengiran Muda Mahkota Pengiran Muda Haji Al-Muhtadee Billah (PMMPMHAMB) Hospital, Tutong, Brunei Darussalam

3Department of Medicine, Raja Isteri Pengiran Anak Saleha (RIPAS) Hospital, Bandar Seri Begawan, Brunei Darussalam

Corresponding author: Vui Heng Chong. Department of Medicine, Pengiran Muda Mahkota Pengiran Muda Haji AlMuhtadee Billah (PMMPMHAMB) Hospital, Jln Sungai Basong, Tutong TA1341, Brunei Darussalam Tel: +673-4260721, Fax: +673-2242690, E-mail: vuiheng.chong@moh.gov.bn
• Received: October 2, 2022   • Accepted: October 11, 2022

Copyright © 2022 Korean Endocrine Society

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

See the letter-reply "Characteristics of Glycemic Control and Long-Term Complications in Patients with Young-Onset Type 2 Diabetes (Endocrinol Metab 2022;37:641-51, Han-sang Baek et al.)" in Volume 37 on page 945.
See the letter "Characteristics of Glycemic Control and Long-Term Complications in Patients with Young-Onset Type 2 Diabetes" on page 641.
We read with interest the article by Baek et al. [1], which showed that patients with young-onset diabetes mellitus (DM) (≤40 years) had higher blood sugar levels at diagnosis and overall poorer control on follow-up, despite initial improvement at 3 months. They were also at a higher risk of developing complications than the middle-age-onset (41 to 59 years) and the late-onset (≥60 years) groups [1]. However, conclusions of that study were based on fasting glucose levels recorded over three time points within the first year of diagnosis and trends correlated with the future development of complications. This assumes that DM control is static.
We recently studied the trend in hemoglobin A1c (HbA1c) (measured approximately at 3- to 6-month intervals, with a mean of 9.1 readings per patient) of 100 consecutive patients with type 2 DM. We categorized patients into three groups: good/satisfactory control (HbA1c ≤8.0%), suboptimal control (8.1% to 9.0%), and uncontrolled (≥9.0%). Based on their latest HbA1c, 44% were categorized as having good/satisfactory control, 6% as having suboptimal control, and 50% as having uncontrolled DM. We then looked at their past HbA1c levels to ascertain trends, and found that 43% of patients recorded fluctuations in control between slight to marked improvement (25%) or deterioration (18%). This shows that control is dynamic and is influenced by many factors, including patients’ awareness, knowledge, compliance with management, and concomitant diseases. Interestingly, the uncontrolled group was also significantly younger, on more DM medications, had more hospitalizations for DM indications, and had a lower estimated glomerular filtration rate (all P values <0.05). We also recently reported our experience with DM and retinopathy, and when we reanalyzed the data (n=341) following the same breakdown of age groups as Baek et al. [1], we found that despite a shorter duration of DM among the young (11.3% of all patients) and middle-age groups, they had poorer DM control and a higher prevalence of diabetic retinopathy than the older group [2]. The results of this study are summarized in the Table 1. In our analysis, the age groups were based on patients’ age at the time of the study and not at the diagnosis of DM.
The control of DM is influenced by a complex interplay of several factors, including genetic factors, especially maturity-onset diabetes of the young, patient-related factors; such as awareness, knowledge, perceptions, and compliance [3,4], and healthcare provider-related factors [5]. Of these, patient-related factors are perhaps the most important. Younger patients are likely to have genetic or epigenetic predispositions, while patient attitudes may also make a major contribution. The fact that hyperglycemia is mostly asymptomatic may lead to a false sense of well-being or a mistaken belief of invulnerability to the effects of chronic hyperglycemia. This can lead to noncompliance with treatment, lifestyle modifications, and clinic attendance.
The findings of Baek et al. [1] are important, especially as they provide evidence that can be used to educate and reinforce the importance of good early control. However, DM control is a dynamic process, and it is important for patients to be aware that fluctuations can occur, and control can deteriorate or improve regardless of the previous levels of control. Nonetheless, further studies are required to confirm if the findings of Baek et al. [1] regarding good early control translate to a reduced risk of future complications and can be extrapolated to other patient populations with different social and cultural norms.

CONFLICTS OF INTEREST

No potential conflict of interest relevant to this article was reported.

Table 1.
Comparisons between the Three Age Groups
Young (<40 years) Moderate (40 to <65 years) Old (65 and older years) P value
HbA1c, mL/min/1.73 m2 8.7±2.1 8.4±1.9 7.7±1.5 0.005a
Proportion of DM control, % 0.018 for trend
 Good 41.0 40.1 58.2
 Suboptimal/poor 59.0 59.9 41.8
Duration of DM, yr 4.5±4.1 8.9±6.9 13.2±8.3 <0.001b
Presence of diabetic retinopathy, % 25.6 25.6% 11.4% 0.029 for trend

Values are expressed as mean±standard deviation.

HbA1c, hemoglobin A1c; DM, diabetes mellitus.

a Analysis of variance (ANOVA): P=0.033 between young and old, and P=0.007 between moderate and old;

b ANOVA: P=0.001 between young and moderate, P<0.001 between young and old, and moderate and old.

  • 1. Baek HS, Park JY, Yu J, Lee J, Yang Y, Ha J, et al. Characteristics of glycemic control and long-term complications in patients with young-onset type 2 diabetes. Endocrinol Metab (Seoul) 2022;37:641–51.ArticlePubMedPMCPDF
  • 2. Raja SA, Chong VH, Rahman NA, Shakir LMP, Knights J. Prevalence and associated factors of diabetic retinopathy among type 2 diabetes mellitus patients in Brunei Darussalam: a cross-sectional study. Korean J Ophthalmol 2022;36:26–35.ArticlePubMedPMCPDF
  • 3. Romakin P, Mohammadnezhad M. Patient-related factors associated with poor glycaemic control among patients with type 2 diabetes mellitus. Aust J Gen Pract 2019;48:557–63.ArticlePubMed
  • 4. Trief PM, Kalichman SC, Wang D, Drews KL, Anderson BJ, Bulger JD, et al. Medication adherence in young adults with youth-onset type 2 diabetes: iCount, an observational study. Diabetes Res Clin Pract 2022;184:109216.ArticlePubMed
  • 5. Romakin P, Mohammadnezhad M. Healthcare providers’ perception of healthcare system factors associated with poor glycemic control among type 2 diabetes patients in Fiji. Rev Diabet Stud 2019;15:49–57.ArticlePubMedPMC

Figure & Data

References

    Citations

    Citations to this article as recorded by  

      Related articles

      Endocrinol Metab : Endocrinology and Metabolism